https://seekingalpha.com/article/4661053-post-holdings-shift-to-pet-food-should-benefit-shares-2024?source=feed_all_articles
Jan 03, 2024 - Post Holdings is facing sluggish demand but is enhancing margins through M&A strategy and increasing pet exposure. Read why POST stock is a Buy.
0
sa:4583692630657959280
0
https://www.rttnews.com/story.aspx?Id=3414261
Jan 02, 2024 - After coming under pressure early in the session, stocks have regained some ground over the course of the trading day on Tuesday but remain mostly lower. The tech-heavy Nasdaq continues to post a particularly steep loss.
0
rttnews:-810053131327078181
0
https://www.cnbc.com/2024/01/04/ken-griffins-hedge-fund-citadel-posts-double-digit-returns-in-2023-but-lags-the-broader-market.html
Jan 04, 2024 - Billionaire investor Ken Griffin's various hedge fund strategists all posted double-digit returns for 2023, but they failed to beat the broader market.
0
cnbc:8949075305548126197
0
https://www.zacks.com/stock/news/2205882/acuity-brands-ayi-to-post-tepid-q1-earnings-here-s-why?cid=CS-ZC-FT-analyst_blog|earnings_preview-2205882
Jan 04, 2024 - Acuity Brands' (AYI) fiscal first-quarter performance is likely to have ailed from softness in the ABL segment and market uncertainty.
zc:4935544936279870377
0
https://www.zacks.com/stock/news/2206507/smart-global-sgh-to-post-q1-earnings-what-s-in-the-cards?cid=CS-ZC-FT-analyst_blog|earnings_preview-2206507
Jan 05, 2024 - SMART Global's (SGH) fiscal first-quarter results are likely to reflect strength across Intelligent Platform Solutions.
zc:-4697425640395958836
0
https://seekingalpha.com/article/4661761-equity-funds-post-their-best-quarterly-returns-since-2020-for-q4-2023?source=feed_tag_etf_portfolio_strategy
Jan 08, 2024 - Equity funds outshine in Q4 2023 with impressive gains, led by Lipper's World Sector Equity Funds. Click here to read our most recent update.
0
sa:945398153009872103
0
https://seekingalpha.com/news/4053188-regeneron-stock-lower-after-early-eylea-sales?source=feed_sector_healthcare
Jan 08, 2024 - Regeneron Pharmaceuticals (REGN) released its early Q4 2023 financials, disclosing over $1.3B U.S. sales from its eye disease therapy Eylea. Read more here.
0
sa:-7389082740151495771
0
https://seekingalpha.com/article/4661442-blackrock-tcp-capital-potential-to-be-a-major-player-in-the-bdc-space-post-merger?source=feed_tag_editors_picks
Jan 08, 2024 - BlackRock TCP Capital announced a merger with BlackRock Capital Investment. Read why the merger is expected to create long-term value for shareholders.
0
sa:6793488722889679527
0
https://www.zacks.com/stock/news/2207159/exelixis-exel-posts-preliminary-2023-results-to-cut-13-jobs?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2207159
Jan 08, 2024 - Exelixis (EXEL) posts preliminary results for 2023 and issues 2024 guidance. The company is set to cut its workforce by 13% in the first quarter of 2024.
zc:741635333740303857
0
https://www.wired.com/story/sec-x-account-compromise/
Jan 09, 2024 - The US financial regulator says its official @SECGov account was “compromised,” resulting in an “unauthorized” post about the status of Bitcoin ETFs.
0
wr:3450877475398467490
0